{"prompt": "['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 11 of 74', 'Other invasive malignancies diagnosed', 'within last year', 'Significant acute or chronic medical or', 'psychiatric condition, disease or', 'laboratory abnormality', 'Women who are pregnant, plan to', 'become pregnant or are lactating', 'Other investigational anti-cancer drugs', 'Use of strong inducers and inhibitors', 'of CYP3A or CYP2C8', 'Investigational medicinal product', 'Dabrafenib 150mg twice daily 12 hours', 'and dosage (Standard,', 'apart, on days 1 - 28 of a 28 day cycle.', 'Continuous arm)', 'Trametinib 2mg once daily, on days 1 - 28 of', 'a 28 day cycle', 'Investigational medicinal product', 'Dabrafenib 150mg twice daily 12 hours', 'and dosage (Experimental,', 'apart, on days 1 - 21 of a 28 day cycle.', 'Intermittent arm)', 'Trametinib 2mg once daily, on days 1 - 14 of', 'a 28 day cycle', 'Route(s) of administration', 'Both drugs are administered orally', 'Maximum duration of treatment', 'Treatment will continue until disease', 'of a patient', \"progression or beyond, at the investigator's\", 'discretion', 'Procedures: Screening &', 'Assessments for all inclusion and exclusion', 'enrolment', 'criteria will be performed within 28 days prior', 'to randomisation. The key assessments are:', 'Written informed consent', 'Computerised tomography (CT) scan', 'nead/chest/abdomen/pelvis', 'Medical review', 'ECOG & Karnofsky performance status', 'Physical Examination & Blood Pressure', 'laematology/biochemistry', 'Electrocardiogram (ECG)', 'Echocardiogram (ECHO)', 'Baseline skin record', 'QoL Questionnaires', 'Women of Child Bearing Potential', '(WCBP): Pregnancy Test as per local', 'practise', 'Confirmation of archival tumour', 'sample availability', 'Procedures prior to', 'Confirmation that the patient satisfies all', 'randomisation', 'the eligibility criteria', 'Treatment period procedures', 'The key assessments are:', 'Clinical assessment and physical', 'examination at 2,4,6 and 8 weeks,', 'then every cycle until disease', 'progression', 'CT scan chest/abdomen/pelvis +/-', 'head at 6 weeks, then every 8', 'calendar weeks until disease', 'progression', 'ECOG & Karnofsky performance status', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 12 of 74', 'Haematology/biochemistry', 'Adverse event documentation', 'QoL questionnaires at 4 weeks, then', 'every calendar 12 weeks until end of', 'the trial', 'End of Trial', 'End of trial for regulatory purposes is defined', 'as 9 months from the date of randomisation', 'of the last patient. Follow-up for survival will', 'be a minimum of 9 months, maximum of 5', 'years from date of randomisation of last', 'patient, as survival beyond this point is', 'unlikely.', 'Procedures for safety monitoring', 'The Trial Management Group (TMG) and', 'during trial', 'Independent Safety Data Monitoring', 'Committee (ISDMC) will regularly review the', 'patient safety data. Pharmacovigilance will be', 'performed by the co-ordinating centre.', 'Criteria for withdrawal of protocol', 'A patient may withdraw, or be withdrawn,', 'treatment', 'from trial treatment for the following', 'reasons:', 'Progression whilst on therapy', 'Unacceptable toxicity', 'Intercurrent illness which prevents', 'further treatment', 'Patient choice', \"Any alterations in the patient's\", 'condition which justifies the', 'discontinuation of treatment in the', \"investigator's opinion.\", 'No further clinical benefit expected', 'Patient misses more than 28', 'consecutive days of planned treatment', 'Following withdrawal of protocol treatment,', 'patients will be followed up according to the', 'protocol visit schedules.', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']\n\n###\n\n", "completion": "END"}